Gaudium IVF and Women Health's Q3 FY 2025-26 Quarterly Results
- 19 Mar 2026
Result Summary
- Gaudium IVF and Women Health Ltd reported a - quarter-on-quarter (QoQ) - in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a - of -.
- Its expenses for the quarter were - by - QoQ and - - YoY.
- The net profit - - QoQ and - - YoY.
- The earnings per share (EPS) of Gaudium IVF and Women Health Ltd stood at 0.59 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 24.61 | 0.00 | 0.00 | - | - |
Total Expenses | 19.65 | 0.00 | 0.00 | - | - |
Profit Before Tax | 4.96 | - | - | NaN% | NaN% |
Tax | 1.33 | 0.00 | 0.00 | - | - |
Profit After Tax | 3.63 | 0.00 | 0.00 | - | - |
Earnings Per Share | 0.59 | 0.00 | 0.00 | - | - |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Gaudium IVF and Women Health Ltd is a company engaged in providing specialized healthcare services, primarily focusing on assisted reproductive techniques and women's health. The company's main products and services include in vitro fertilization (IVF) treatments, fertility consultations, and a range of women's health services. Operating within the healthcare industry, Gaudium IVF aims to offer advanced medical solutions to improve reproductive health and outcomes for women. The company is known for its expertise in fertility treatments, and it plays a significant role in the growing field of reproductive medicine. Recent developments regarding the company's strategic initiatives or market expansions are not available at this time.
Revenue
For the third quarter of the fiscal year 2026 (Q3FY26), Gaudium IVF and Women Health Ltd reported a total income of ₹24.61 crores. No comparative data is available for the previous quarter (Q2FY26) or the same quarter of the previous year (Q3FY25), as both are recorded as ₹0.00 crores. Consequently, quarter-over-quarter (QoQ) and year-over-year (YoY) changes cannot be calculated from the provided data. The revenue data highlights the company's performance for the current quarter without historical context from past quarters or years.
Profitability
In Q3FY26, Gaudium IVF and Women Health Ltd recorded a profit before tax of ₹4.96 crores. After accounting for a tax expense of ₹1.33 crores, the profit after tax stood at ₹3.63 crores. Earnings per share for the quarter were ₹0.59. Due to the lack of comparative financial data from Q2FY26 and Q3FY25, changes in profitability metrics over time, such as QoQ and YoY trends, cannot be determined. The profitability figures for the current quarter are presented without the ability to assess changes or trends over time.
Operating Metrics
The company's total expenses for Q3FY26 were ₹19.65 crores. No comparative data for total expenses is available for previous quarters or years, as both Q2FY26 and Q3FY25 are recorded as ₹0.00 crores. Consequently, operating metrics such as expense trends and efficiency ratios cannot be assessed. The financial data provides a snapshot of the company's operating performance for Q3FY26 without historical comparisons.
FAQs
Gaudium IVF and Women Health Ltd announced its Q3 FY 2025-26 results on 19 March, 2026.
Gaudium IVF and Women Health Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
Key highlights of Gaudium IVF and Women Health Ltd Q3 FY 2025-26 results include:
- Revenue: ₹24.61 crore
- Net Profit: ₹3.63 crore
- EBITDA: ₹6.65 crore
- Year-over-Year Growth: undefined
- Quarter-over-Quarter Growth: undefined
Gaudium IVF and Women Health Ltd reported a net loss of ₹3.63 crore in Q3 FY 2025-26, reflecting a undefined year-over-year growth.
Gaudium IVF and Women Health Ltd posted a revenue of ₹24.61 crore in Q3 FY 2025-26.